Rhumbline Advisers Has $1.35 Million Position in Harrow, Inc. (NASDAQ:HROW)

Rhumbline Advisers cut its position in shares of Harrow, Inc. (NASDAQ:HROW) by 2.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 40,096 shares of the company’s stock after selling 931 shares during the period. Rhumbline Advisers owned 0.11% of Harrow worth $1,345,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Quest Partners LLC acquired a new stake in Harrow during the 3rd quarter valued at $29,000. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Harrow by 21.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,283 shares of the company’s stock valued at $57,000 after purchasing an additional 227 shares during the period. Huntington National Bank bought a new position in shares of Harrow in the third quarter valued at about $164,000. Virtu Financial LLC acquired a new stake in shares of Harrow during the 3rd quarter worth about $271,000. Finally, Principal Financial Group Inc. bought a new stake in shares of Harrow during the 3rd quarter worth about $329,000. 72.76% of the stock is currently owned by institutional investors and hedge funds.

Harrow Stock Performance

NASDAQ HROW opened at $26.25 on Thursday. Harrow, Inc. has a 12-month low of $9.30 and a 12-month high of $59.23. The firm has a 50-day moving average price of $32.04 and a two-hundred day moving average price of $39.75. The company has a market capitalization of $934.89 million, a P/E ratio of -27.93 and a beta of 0.69. The company has a quick ratio of 1.44, a current ratio of 1.55 and a debt-to-equity ratio of 3.23.

Analyst Ratings Changes

Several research firms have weighed in on HROW. B. Riley lowered their price target on shares of Harrow from $73.00 to $69.00 and set a “buy” rating on the stock in a report on Wednesday, December 4th. HC Wainwright started coverage on Harrow in a research note on Thursday, February 6th. They set a “buy” rating and a $57.00 target price on the stock.

Harrow Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.